Follow
← Back
Medicines · Interactions

Rifaximin — interactions

Other medicines, foods and herbal products can change how Rifaximin works. Everything on this page comes from Rifaximin's own FDA-approved label — the same source as the main guide.

← Back to the full Rifaximin guide

⚠ Caution: Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.

Medicines named in Rifaximin's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

P-glycoprotein Inhibitors

Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.

Warfarin Changes in INR

Have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin.

CYP3A4 Substrates

An in vitro study has suggested that rifaximin induces CYP3A4 . However, in patients with normal liver function, XIFAXAN at the recommended dosing regimen is not expected to induce CYP3A4.

Rifaximin's label names 2 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Rifaximin's label have interaction pages of their own:

Read the full interactions section from Rifaximin's label

Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.

7.1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed .

7.2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin.

7.3 CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 . However, in patients with normal liver function, XIFAXAN at the recommended dosing regimen is not expected to induce CYP3A4. It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.

Rifaximin guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 27 Aug 2025) · NepalDoc medicine catalog · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Rifaximin's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.